Comparing the current results to its competitors, Integra Lifesciences Holdings reported Revenue increase in the 2 quarter 2026 by 0.76 % year on year. The revenue growth was below Integra Lifesciences Holdings's competitors' average revenue growth of 11.27 %, achieved in the same quarter.
Integra Lifesciences Holdings Corp achieved net profit of $4.48 millions compared to a net loss of $-484.07 millions recorded in the same quarter a year ago.
Integra Lifesciences Holdings's Comment on Competition and Industry Peers
The company faces competitive challenges related to its financial leverage, which may restrict its ability to compete effectively against less leveraged competitors. Its competitive position depends in part on proprietary technologies and manufacturing processes protected by patents and trade secrets. However, patents may be subject to challenges, narrowing, invalidation, or unenforceability, and competitors may develop similar products outside the scope of these patents. Trade secrets are difficult to safeguard, and there is no guarantee that others will not independently develop similar proprietary information or obtain access to the company's trade secrets. The company uses confidentiality agreements to protect its trade secrets.
With modest revenue growth of 0.76 % within Overall company, Integra Lifesciences Holdings Corp failed to increase sales with the same pace, like most of company's peers within this division. << More on IART Market Share.
*Market share is calculated based on total revenue.
News about Integra Lifesciences Holdings Corp Contracts
Publicly Traded Peers of Integra Lifesciences Holdings Corp
Clearpoint Neuro Inc Share Performance
+26.33%
One Year
Clearpoint Neuro Inc
Profile
Clearpoint Neuro Inc's business model revolves around providing advanced deep brain stimulation (DBS) solutions for the treatment of neurological disorders. It focuses on developing and commercializing innovative medical devices, software, and services that enable precise and accurate targeting for electrode placement during neurosurgical procedures.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Meihua International Medical Technologies Co Ltd Share Performance
-78.26%
This Year
Meihua International Medical Technologies Co Ltd
Profile
Meihua International Medical Technologies Co. Limi operates on a business model focused on the development and distribution of medical technologies and solutions. The company aims to deliver innovative and quality medical equipment to healthcare providers and institutions globally. By leveraging their expertise and partnerships, Meihua strives to enhance healthcare outcomes and contribute to the advancement of medical technology.
Inspiremd Inc is a medical device company that develops and commercializes stent systems for the treatment of coronary artery disease. Their business model revolves around the production and distribution of their proprietary stent systems to healthcare providers worldwide.
Sources:
Integra Lifesciences Holdings Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Integra Lifesciences Holdings Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
